Applied DNA Sciences

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Applied DNA Sciences reports strong Q1 results and eyes revenue diversification

Applied DNA Sciences demonstrated robust revenue growth and operational improvements in Q1 2023, driven by key revenue streams and cost management.
While facing financial challenges and dependency on key projects for guidance, the company is strategically positioned for growth and innovation.
Opportunities in nucleic acid therapies, strategic partnerships, and revenue diversification present a promising outlook for Applied DNA Sciences.

Applied DNA Sciences adapts focus to genomics amid revenue challenges

Applied DNA Sciences faced revenue challenges in Q2 2023 but showcased resilience through strategic focus on pharma genomics testing and DNA tagging solutions.
The company's emphasis on efficiency in mRNA manufacturing and pursuit of acquisitions signal a proactive approach to enhancing market competitiveness and technological capabilities.
While financial challenges persist, opportunities in genetic testing and compliance solutions position Applied DNA Sciences for future growth and market leadership.

Applied DNA Sciences reports revenue decline and operational challenges

Applied DNA Sciences faced challenges in revenue decline and increased operating expenses in Q3 2023, leading to an operating loss and concerns about its financial sustainability.
Despite these challenges, the company demonstrated strengths in enhancing mRNA initiatives through the Spindle Biotech acquisition and Linea IVT platform, as well as continued growth in supply chain traceability.
Opportunities lie in expanding partnerships with evaluation customers, leveraging the Linea IVT platform's capabilities, and exploring new revenue streams in DNA tagging applications.

Applied DNA Sciences reports Q4 revenue decline, focuses on growth

Applied DNA Sciences faced a challenging quarter with declining revenues and operating losses, but maintained a focus on innovation and growth.
The company's strategic strengths lie in biotherapeutic manufacturing, successful acquisitions, and plans for revenue expansion through the Linea IVT platform.
However, challenges such as Nasdaq compliance issues and financial pressures require careful management and strategic decision-making.
Opportunities for revenue growth and market expansion exist through customer relationships, product development, and addressing regulatory requirements.

Applied DNA Sciences tackles financial challenges while eyeing revenue growth

Applied DNA Sciences faces challenges with declining revenues and profitability, necessitating a focus on cost management and revenue generation to improve financial health.
Despite financial pressures, the company's strategic strengths lie in innovative product development, quality control measures, and efforts to enhance operational efficiency.
Opportunities for revenue growth exist through the commercialization of Linea IVT platform, international expansion, and partnerships, signaling potential for market expansion and increased customer adoption.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied DNA Sciences Inc (NASDAQ:APDN) plans to introduce its Linea 2.0 COVID-19 Assay for the SARS-CoV-2 E and N genes after submitting its validation data to the New York State Department of Health (NYSDOH) in the next few days. The Company also announced that its EUA-authorized Linea COVID-19 Assay Kit likely exhibits a unique double S-gene target failure specific to the Omicron variant.

Applied DNA Stock Surges On Launch Plans For Linea 2.0 COVID-19 Assay For Omicron Variant

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Introduces Linea 2.0 COVID-19 Assay Kit for the detection of Omicron variant. 1.0 test impacted by Omicron; can be used as a reflex test for Omicron.

Applied DNA Announces Strategy to Address Omicron SARS-CoV-2 Variant, Introduces Linea™ 2.0 COVID-19 Assay Kit

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #CARTcell--Applied DNA subsidiary LineaRx receives repeat orders and secures new CRO customer for LinearDNA. Demand for therapeutic DNA is driving inquiries.

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #CARTcell--The authors' findings coincide with the industry's growing interest in alternatives to pDNA for CAR T-cell therapies.

Research Publication Demonstrates Utility of Applied DNA's LinearDNA™ in Non-Viral CAR T Manufacturing Systems

STONY BROOK, N.Y. & WATER MILL, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19diagnostics--Applied DNA and CLEARED4 stand ready to help large employers prepare for compliance with the OSHA mandate for COVID-19 vaccination and testing.

Applied DNA and CLEARED4 Offer Fast, Cost-Effective and Turnkey Integrated Solution for Compliance with OSHA Mandate for COVID-19 Vaccination and Testing

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--EUA request for rapid alternative to NGS to identify mutations that may negatively impact efficacy of anti-SARS-CoV-2 monoclonal antibody treatments.

Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ SARS-CoV-2 Mutation Panel

STONY BROOK, N.Y. & KANPUR, India--(BUSINESS WIRE)---- $APDN #CertainT--Ganesha will deploy CertainT(R), Applied DNA's traceability system, to tag an initial production of recycled PET at Ganesha's facilities in India.

Ganesha Ecosphere and Applied DNA to Deploy CertainT® Platform to Secure Recycled Polyester Supply Chain

The stock price of Applied DNA Sciences Inc (NASDAQ: APDN) increased by over 20% yesterday. This is why it happened.

APDN Stock: Why It Significantly Increased

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #covid19--Applied DNA adds Sarah Lawrence College as COVID-19 testing customer.

Applied DNA Implements safeCircle™ COVID-19 Testing Program at Sarah Lawrence College

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #supplychainsecurity--Applied DNA Receives Purchase Orders Totaling $1.6M to Tag Textile Fibers; Progressing Textile Projects Representing New Commercial Opportunities

Applied DNA Receives Purchase Orders Totaling $1.6 Million to Tag Textile Fibers

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #cannabis--Companies Advances Cannabis Partnership.

Applied DNA Announces CertainT® Platform Support for TruTrace StrainSecure™ 2.0 for Next Generation Cannabis Tagging, Testing and Tracking

Aurora Cannabis

Canopy Growth

Flora Growth Corp

Akerna Corp

Lexaria Bioscience

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

5 Cannabis Stocks That Lit Up Wall Street This Week

Flora Growth Corp. (NASDAQ:FLGC) announced Thursday it has signed agreements with TruTrace Technologies, Inc. (CSE:TTT) (OTCQB:TTTSF) and Applied DNA Sciences, Inc. (NASDAQ:APDN) to launch a complete and differentiated global cannabis product validation and authentication platform for consumers, distributors and government regulators. Flora will use TruTrace's blockchain-based SaaS software to track inventory and product quality testing, including molecular tagging through Applied DNA's Certain T platform to track the cannabis flower and derivatives originating from its Cosechemos cultivation and extraction facility.

Flora Growth Launches Cannabis Product Validation And Authentication Platform With TruTrace And Applied DNA Sciences

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #cannabis--Applied DNA Enters Into Master Services Agreement with Flora Growth for Cannabis Validation and Secures First Statement of Work.

Applied DNA Enters into Master Services Agreement with Flora Growth for Cannabis Validation and Authentication, Secures First Statement of Work Contract

MIAMI & TORONTO--(BUSINESS WIRE)--Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce it has signed agreements with TruTrace Technologies, Inc. (CSE: TTT; OTCQB: TTTSF) (“TruTrace”) and Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) to launch a complete and differentiated global cannabis product validation and authentication platform for consumers, distributors,

Flora Growth Launches Cutting-Edge Global Cannabis Distribution Strategy, Implements Pharmaceutical Standards For Its Supply Chain

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA CEO to present at upcoming H.C. Wainwright 23rd Annual Global Investment Conference (virtual).

Applied DNA to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

Applied DNA Sciences Inc's (NASDAQ:APDN) subsidiary Applied DNA Clinical Labs has been awarded a testing contract by Suffolk County Community College. Also Read:   Applied DNA Receives COVID-19 testing contract by the City University of New York

Applied DNA Stock Jumps On New COVID-19 Testing Contract

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA to monitor for the prevalence of COVID-19 among Suffolk County Community College's unvaccinated staff and faculty.

Applied DNA Awarded Suffolk County Community College COVID-19 Testing Contract

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q3 2021 Results - Earnings Call Transcript

Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -91.67% and -50.51%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Applied DNA Sciences (APDN) Reports Q3 Loss, Lags Revenue Estimates

Shares of Applied DNA Sciences (NASDAQ:APDN) fell 7.8% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 36.11% year over year to ($0.46), which missed the estimate of ($0.22).

Recap: Applied DNA Sciences Q3 Earnings

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVIDDiagnostics--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the three and nine months ended June 30, 2021. “We delivered excellent year-over-year revenue growth in the fiscal third quarter while laying the groundwork to secure a recently awarded COVID-19 testing services contract that has potential to be th

Applied DNA Announces Third Quarter Fiscal 2021

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVIDDiagnostics--Applied DNA Sciences Schedules FQ3'21 Investor Call and Webcast.

Applied DNA Schedules Fiscal 2021 Third Quarter Financial Results Conference Call and Webcast for Thursday, August 12, 2021

Applied DNA Sciences Inc's (NASDAQ:APDN) subsidiary Applied DNA Clinical Labs LLC has received a COVID-19 testing contract by the City University of New York (CUNY) to facilitate the University's reopening in the fall. The contract term is 12 months, has a maximum value not to exceed $35.0 million, and contains no minimum weekly testing commitment.

Why Is Applied DNA Stock Soaring Higher Today?

The stock price of Applied DNA Sciences Inc (NASDAQ: APDN) increased by over 33% during intraday trading. This is why it happened.

News for Applied DNA Sciences Stock (APDN)